The current study identifies CCR8
+ regulatory T cells (T reg cells) as drivers of immunosuppression. We show that in human peripheral blood cells, more than 30% of T reg up-regulate CCR8 following activation in the presence of CCL1. This interaction induces STAT3-dependent up-regulation of FOXp3, CD39, IL-10, and granzyme B, resulting in enhanced suppressive activity of these cells. Of the four human CCR8 ligands, CCL1 is unique in potentiating T reg cells. The relevance of these observations has been extended using an experimental model of multiple sclerosis [experimental autoimmune encephalomyelitis, (EAE)] and a stabilized version of mouse CCL1 (CCL1-Ig). First, we identified a self-feeding mechanism by which CCL1 produced by T reg cells at an autoimmune site up-regulates the expression of its own receptor, CCR8, on these cells. Administration of CCL1-Ig during EAE enhanced the in vivo proliferation of these CCR8 + regulatory cells while inducing the expression of CD39, granzyme B, and IL-10, resulting in the efficacious suppression of ongoing EAE. The critical role of the CCL1-CCR8 axis in T reg cells was further dissected through adoptive transfer studies using CCR8 −/− mice. Collectively, we demonstrate the pivotal role of CCR8 + T reg cells in restraining immunity and highlight the potential clinical implications of this discovery.
T wo major populations of CD4
+ regulatory T cells (T reg cells), defined by whether they express the forkhead box protein 3 transcription factor (FOXp3), are thought to play a key role in the maintenance of self-tolerance (1) (2) (3) (4) (5) (6) (7) (8) . Both FOXp3 + and FOXp3 − subtypes participate in the regulation of inflammatory autoimmunity and in the maintenance of self-tolerance by various mechanisms, including regulating the biological function of effector TH1 and TH17 CD4 + T cells (6, 7, (9) (10) (11) (12) . CD4 + FOXp3 − regulatory T cells can be categorized as T regulatory-1 cells (Tr1), which primarily produce , and Th3, which express high levels of TGFβ (16) .
Chemokines are small (∼8-14 kDa) secreted proteins, structurally similar to cytokines, that regulate cell trafficking through interactions with a subset of seven transmembrane G protein-coupled receptors (GPCRs) (17) , and many of them are associated with chemotaxis of leukocytes to inflammatory sites (18) (19) (20) . Almost 15 y ago we showed that, in addition to their role in chemoattraction, chemokines are also involved in directing effector CD4
+ T-cell (T eff ) polarization, by showing that the CXCR3 ligand CXCL10 directs the lineage development of TH1 cells (21, 22) . More recently we identified two different chemokines that are involved in the lineage development of Tr1 cells (23, 24) . The current study focuses on FOXp3
+ T reg cells and on the interplay between CCR8 and its ligands.
In mouse, the chemokine receptor CCR8 is expressed principally on T reg cells and also notably on small fractions of TH2 cells, monocytic cells, and NK cells (25) (26) (27) (28) , but not TH1 cells (29, 30) . A similar expression pattern is seen in humans, in which CCR8 is additionally found on ∼2% of CD8 + cells (30) . CCR8 is known to be critical for T reg function. For example, Coghill et al. recently showed in a graft versus host disease (GVHD) model, donor T reg cells lacking CCR8 were severely impaired in their ability to prevent lethal GVHD (31) . However, the underlying mechanisms of such observations remained unclear.
The current study uncovers the mechanistic basis by which the CCR8-CCL1 axis potentiates T reg cells, its relevance to human biology, and explores the clinical implications of these findings using an experimental autoimmune disease of the central nervous system (CNS) (32) .
Results
Of the Four CCR8 Ligands, CCL1 Is Unique in Potentiating the Suppressive Function of Human T reg Cells. Human CCR8 has four known ligands: CCL1, CCL8, CCL16, and CCL18 (33). First we examined whether one or more of the four human CCR8 ligands may enhance the suppressive activity of human T reg cells. Fig. 1 summarizes data obtained from 10 different healthy donors, indicating that of the four human CCR8 ligands, CCL1 was unique in potentiating the suppressive function of human T reg cells, detected as an enhanced suppression of T eff proliferation ( Fig. 1 A-C) . Because CCR8 is considered to be the exclusive receptor for CCL1 (26) , we sought to confirm that these effects were achieved via CCR8 signaling. As shown in Fig. 1D , antihuman CCR8 blocking mAb abolished CCL1-mediated effects in this assay.
Independently, each human CCR8 ligand was tested in a fluorometric imaging plate reader (FLIPR) assay (34) configured to detect the induction of intracellular Ca 2+ flux in response to CCR8 activation in CHO-K1 cells overexpressing human CCR8. As shown in Fig. S1 , CCL1 induced a dose-dependent up-regulation of
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+ regulatory T cells (T reg cells) as drivers of immunosuppression and provides compelling evidence of a self-feeding mechanism by which, at an autoimmune site, CCL1 produced by FOXp3 + T reg cells upregulates the expression of its own receptor, CCR8, on these cells, and potentiates their in vivo proliferation and suppressive activities as driver T reg cells. The suppression of ongoing autoimmunity by a stabilized version of the chemokine (CCL1-Ig) highlights the translational potential of these findings.
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2+ flux in response to CCR8 activation, whereas no effect was seen in the presence of CCL8, CCL16, or CCL18. We note that these data differ from a publication showing that CCL18 may also induce Ca 2+ flux via CCR8 (33) . Collectively, these data show that of the four CCR8 ligands, only CCL1 induces Ca 2+ flux and potentiates the suppressive activity of these cells.
CCL1 Potentiates Human T reg Cells by Inducing CCR8, FOXp3, CD39, Granzyme B, and IL-10 Expression. At 36 h postactivation of cultured human T reg cells that were, or were not, supplemented with CCL1, they were examined for the transcription of various genes known to be associated with the T reg phenotype (7) by real-time PCR. We observed between 4-and 5-fold increases in the transcription of FOXp3 and CCR8 (P < 0.0001), a 3.7-fold increase in the transcription of CD39 and a 2.5-fold increase in granzyme B and IL-10 (P < 0.01) ( Fig. 2A) . Results were then confirmed at the protein level by flow cytometry (Fig. 2 B-D) . We observed that during in vitro activation in the presence of CCL1, the expression of CCR8 on CD4
low T reg increases from 2.65% to 36% of the cells (Fig. 2B) , whereas its expression on CD4 An increased expression of FOXp3 (from 89.6% to 95.7%, P < 0.01) was also observed in these CD4
low T cells (Fig.  2C ). Further analysis of FOXp3 + T cells (Fig. 2D ) revealed a significant increase in CD39 (from 4.43% to 16.1%, P < 0.0001), granzyme B (from 3.25% to 18.3%, P < 0.0001), and IL-10 (from 6.26% to 15.4%, P < 0.0001). Further dissection of the differential transcription of these molecules has been conducted in the murine setup and showed preferential early transcription of CCR8 and FOXp3, as discussed later (Fig. S2) .
A subsequent set of experiments was conducted to determine whether CCL1 might also increase FOXp3 expression in CD4 Suppression assays were conducted as described for A above, with or without addition of an anti-CCR8 blocking mAb. Results of one of three independent experiments are shown as mean of triplicates ± SE. Significance was determined by two-tailed unpaired Student's t test (*P < 0.01). 
CD127
low T cells as described above, and 36 h later the expression of various gene products was determined by flow cytometry. A representative plot is shown together with a scatterplot summarizing five different samples of healthy donors. Significance was determined by unpaired Student's t test (B) P < 0.0001, (C) P < 0.01, and (D) P < 0.0001. (E) CCL1 does not convert FOXp3 − T cells into T reg cells: CCL1 was added to cultured
TGF-β was used as a positive control for induction of iT reg cells.
CD39, granzyme B, and IL-10 in these cells without converting FOXp3
CCL1-Induced Potentiation of T reg Cells Is STAT3 Dependent. Fig. 3A shows that CCL1 induces the phosphorylation of STAT3 but none of the other STAT proteins, as determined by phospho-specific detection using flow cytometry (35) , and that this phosphorylation is selective to CCR8 + cells. To further validate this observation, we assessed CCL1-mediated effects in the presence or absence of a STAT3 inhibitor. As shown in Fig. 3B , flow cytometry analysis confirmed that inhibiting STAT3 prevented the up-regulation of CD39 in FOXp3
+ T reg cells (change from 7.25% to 19.8% (CCL1 alone) vs. 13% (CCL1 with inhibitor). Similarly, ELISA detection confirmed abolition of CCL1-induced granzyme B (Fig.  3C ) and IL-10 ( Fig. 3D) following STAT3 inhibition.
Collectively, these results show that in human cells, CCL1 potentiates T reg cells first by inducing the expression of its target receptor on CD4 + CD25 + C127 low T cells followed by the induction of STAT3-dependent increase of CD39, granzyme B, and IL-10, which are key drivers of the suppressive function of these cells.
We then sought to determine whether similar CCL1-drived pathways exist in mouse, using murine CD4 + T cells. As shown in Fig.  S2A , of the three known murine ligands for mouse CCR8 (CCL1, CCL8, and CCL16), CCL1 exclusively enhanced the suppressive activities of mouse T reg cells (41% increase, P < 0.01) in an ex vivo T eff suppression assay. The dependence on CCR8 of these effects was confirmed using T cells isolated from CCR8-deficient mice. As shown in Fig. S2B , murine CCL1 enhanced the suppressive activity of T reg cells from wild-type mice (72% increase, P < 0.001) but had no effect on T reg cells obtained from CCR8
−/− mice. In experiments corresponding to those in the human system described in Fig. 2 , we have similarly shown that mouse CCL1 enhances the transcription of CCR8, FOXp3, granzyme B, CD39, and IL-10 in murine T reg cells (Fig. S2C) . Here we also compared the relative increase of the transcription of these genes after 16 and 36 h, showing that at the earliest time point, the increased transcription of FOXp3 and CCR8 is mostly dominant over granzyme B, CD39, and IL-10. We also verified these results at the protein level and confirmed that blockade of STAT3 abrogates this increase (Fig. S2 D and E) .
Finally, we examined whether CCL1 can polarize murine FOXp3
e., induction of induced T reg (iT reg )], as reported for TGFβ (36) . (Fig. 4B) , suggesting that these cells were potentially the principal source of CCL1. Comparative analyses showed that within the inflamed CNS, CCL1 is largely transcribed by FOXp3 + T reg cells but not by microglia cells (Fig. 4C) .
Next, we examined the relative number of CCR8 + cells within the CD4
+ FOXp3 subset at the inflamed CNS and compared the expression of granzyme B, CD39, and IL-10 in CCR8 + FOXP3 + and CCR8 − FOXP3 + CD4 + T cells within the CNS (Fig. 4D) . We found that at the peak of disease, about 9% of CD4 ). Collectively, these data suggest an autocrine role for the CCL1-CCR8 axis in potentiating T reg cells at the autoimmune site.
CCL1-Ig Suppress Ongoing EAE by Inducing CCR8 and Potentiating T reg Cells via This Receptor. We sought to investigate whether administration of CCL1 could affect ongoing EAE. The short in vivo half-life of chemokines limits their exposure following systemic administration. Therefore, using similar strategies for extending half-life to those that we have previously used for CXCL12 (24) , CXCL10, and CXCL11 (23), we generated a mouse CCL1-Ig fusion protein (Fig. S3 A and B) . This construct retains the biological activities of the native chemokine, including chemoattraction 
low T cells undergoing anti-CD3/anti-CD28-induced activation were supplemented with CCL1 with or without a STAT3 inhibitor. After 72 h, granzyme B and IL-10 levels were recorded by ELISA. Results of one of three independent experiments with similar data are presented as mean triplicates ± SE. Significance was determined by two-tailed unpaired Student's t test (*P < 0.001).
( Fig. S3C ) and ERK1/2 phosphorylation of the BW5147 CCR8 + thyoma cell line (37) (Fig. S3D) . Preliminary pharmacokinetic (PK) analysis in mice confirmed that CCL1 formatted as a Fcfusion protein had an acceptable exposure and half-life to enable its use in disease models (Fig. S3E) . Pharmacodynamic (PD) analysis confirmed that it retained biological activity in vivo, achieving a durable induction of FOXP3 +
CD39
+ T reg cells both in the spleen and in the spinal cord (Fig. S4) . We were therefore able to investigate the potential therapeutic effect of CCL1-Ig on ongoing EAE. Fig. 5A summarizes data from one of three independent experiments with similar observations, showing that administration of CCL1-Ig during ongoing EAE rapidly suppressed the development and progression of disease (day 21 mean maximal score of 1 ± 0.13 compared with 2.5 ± 0.23, P < 0.01). Clinical observations were confirmed histologically (Fig. 5B, mean histological score 0.5 ± 0.1 compared with 2.6 ± 0.3 in and 2.5 ± 0.3 in control groups, P < 0.01).
Protective administration of CCL1-Ig led to a significant increase in the relative number of FOXp3 + T reg cells both in the periphery (spleen) and the CNS, and of the relative expression of CCR8 on these cells (Fig. S5A) . As the relative increase in FOXp3 + T cells is systemic, it is not likely that it is due to differential migration of cells, but rather increased expression of FOXp3 and/or increased in vivo proliferation of FOXp3 + T cells. We also tested 5-bromo-2′-deoxyuridine (BrdU) uptake in this in vivo model (Fig. S5B) showing a significant increase in the proliferative response of FOXp3 + T cells at the CNS and spleen of CCL1-Ig-treated mice (P < 0.01) combined with reduced proliferation of FOXp3 − CD4 + T cells (P < 0.01), which could be due to the increased suppressive effect of FOXp3 + T reg cells. Furthermore, the relative expression of CD39, granzyme B, and IL-10 significantly increased in these CCR8
+ T cells following CCL1-Ig administration ( Fig. S5C , P < 0.001). Collectively, these data suggest that CCL1-Ig suppresses ongoing EAE, in part, by inducing the proliferative response of T reg cells and potentiating their activity via CCR8, which is induced by itself via CCL1.
The in Vivo Suppressive Activity of CCL1 on T reg Cells Is CCR8 Dependent.
We conducted a set of experiments to further examine the relevance of the interplay between CCL1 and its receptor CCR8 in restraining EAE. The experimental system included CCR8
−/− mice reconstituted with CD4
+ T reg cells from either CCR8 −/− or WT mice followed by administration of CCL1-Ig. To optimize the methodology of the adoptive transfer protocol, we performed pilot studies in which mice were administered 5 × 10 (Fig. S6) , and that administration of CCL1-Ig to mice lacking CCR8 had no effect on the severity of disease (Fig. S7A) , in contrast were separated into groups with comparable disease scores (n = 9 mice per group, from which three were killed at the peak of disease). On days 13, 15, 17, and 19 after the induction of disease mice were injected (i.p.) with either PBS, 300 μg per mouse of mCCL1-Ig or IgG isotype control. An observer blind to the experimental protocol monitored the development and progression of disease. The results (n = 9 mice per each group until day 17 and n = 6 from day 17 onward) are shown as the mean maximal score ± SE. The results show one of three independent experiments with similar data. One-way ANOVA for paired data was used to determine the significance of the time-response curves (*P < 0.01). The arrows indicate the days of mCCL1-Ig or IgG administration. (B) Histopathological evaluation: At the peak of disease (day 17), three representative mice per group were killed and lumbar spinal cord was subjected to histological analysis (18 sections per spinal cord) using a score of 0-3 as described in ref. 63 (see also SI Methods). The mean histological score ± SE was calculated for each treatment group. Representative histological sections are shown, and a statistical analysis of all sections is also given. Significance was determined by two-tailed unpaired Student's's t test (*P < 0.001).
to its effect on WT mice (Fig. S7B) . Importantly, we observed that in CCR8 −/− mice reconstituted with CCR8 + T reg cells (Fig. S7C ) administration of CCL1-Ig rapidly suppressed disease (day 21, 1.5 ± 0.166 compared with 3 ± 0.23, P < 0.01), whereas reconstitution with T reg cells from CCR8 −/− mice was without effect (Fig. S7D ). This finding further indicates the pivotal role of the CCL1-CCR8 axis on T reg cells in the regulation of EAE.
Because the mechanism of T reg potentiation includes upregulation of IL-10, we sought to address whether increased production of IL-10 in T reg cells is the principal mechanism of CCL1-induced potentiation of these cells. An in vitro suppression assay comparing T reg and effector CD4 + T cells from WT or IL-10 KO mice revealed that CCL1-mediated potentiation of T reg cells was achieved even in the absence of IL-10 (Fig. S8A) . Subsequently, we used the adoptive transfer model to show that CCL1-Ig effectively suppresses EAE when acting on T reg cells from IL-10 KO mice (Fig.  S8B) . Collectively, these data imply CCL1 may potentiate T reg cells even in the absence of IL-10.
Our adoptive transfer experiments (Fig. S7) show that the interaction between CCL1 and CCR8 on T reg cells is essential for suppressing EAE. However, this observation still does not exclude the possibility that CCL1 may also affect the development and progression of disease via its interaction on other CCR8 + population that express high levels of CCR8 (38) . Th2 cells produce IL-4 to mediate their biological function, so we examined whether CCL1 potentiates IL-4 production in these cells but found no evidence of such an effect (Fig. S9) , consistent with the regulatory effect of CCL1 on CD4 + T cells being predominantly T reg dependent.
Discussion
The current study focuses on the interplay between the chemokine receptor CCR8 and its ligands, particularly CCL1, and its role in the generation and maintenance of active tolerance. We show that of the known CCR8 ligands, CCL1 is unique in its ability to induce Ca 2+ flux via this receptor and to potentiate the suppressive activities of T reg cells. We also show that this chemokine up-regulates the expression of its target receptor on these cells (in vitro and in vivo) and by so doing, further induces their suppressive activities in an autocrine loop. Evidence from the EAE model suggests that at the autoimmune site, CCL1 is largely produced by T reg cells to potentiate their suppressive function in an autocrine loop, further emphasizing the key role of this interaction in the regulation of autoimmunity.
We suggest two complementary pathways by which T reg cells, via the CCR8-CCL1 interaction, function as driver suppressor cells in vivo: (i) the induction of their proliferation to increase their relative number and (ii) an increased expression of key mediators of suppressive immune regulation. These include: the suppressor cytokine IL-10, which suppresses both innate and specific immune activities (39); granzyme B, which is capable of specifically killing antigen-presenting B cells, thus limiting autoimmunity (40); and CD39, which decreases the extracellular concentration of ATP, and has recently been tightly associated with control of autoimmunity within the CNS (41) . Interestingly, we showed that CCL1 could effectively potentiate CCR8 + T reg cells lacking IL-10 ( Fig. S7 ). This result implies that IL-10 could be important, but not critical, for CCL1-induced potentiation of T reg cells. Future complementary studies using IL-10R KO mice are required to investigate whether there is an alternative cytokine that induces IL-10R-dependent activation of STAT3 in these mice.
Even though CCR8 is expressed by "driver" T reg cells, its expression is not exclusive to these cells (28, 30, (42) (43) (44) (45) . Our results (Fig. S7) showing that CCL1-Ig rapidly suppresses disease in mice reconstituted with T reg cells from wild-type but not CCR8-deficient mice suggest that T reg cells are the dominant cell type by which CCL1 achieves its beneficial effects. Nevertheless, we do not exclude the possibility that the interaction of CCL1 with other CCR8
+ cells may also affect the dynamics of disease. A further question relates to the role of STAT3 in T reg potentiation. The involvement of STAT3 in the polarization of both Th17 and FOXp3 + T reg cells (46-49) might explain, in part, the plasticity of the Th17/T reg pathways (10, 50) and its implications in the regulation of immunity, particularly within the gut (51) (52) (53) . Moreover, in Th17 cells STAT3 phosphorylation is induced by the proinflammatory cytokines IL-6 and IL-23 (48) . Taken together, these data imply that STAT3 phosphorylation is induced by different cytokines/chemokines in different cell types and that the biological consequences of this phosphorylation may be cell type specific and/ or that alternative signaling pathways, yet to be identified, are required for the CCL1-CCR8-induced potentiation of T reg cells.
We note, and draw some parallels with, previous reports that low dose IL-2 rapidly induces the in vivo expansion of T reg cells to suppress type I diabetes in nonobese diabetic mice, even though the in vitro effect of low-dose IL-2 on T reg expansion was very limited (54, 55) . These low-dose IL-2 studies were later extended to clinical trials, e.g., for hepatitis C virus-induced vasculitis (56) , and GVHD (57) . Indeed, the induction of in vivo expansion of T reg cells as a therapeutic strategy for autoimmune disease remains an area of intense interest. However, our data suggest that intervention with a CCL1-based therapy may be preferred to IL-2, because the latter has the potential, even at low dose, to activate effector T cells and NK cells and potentially aggravate disease (58) .
From the translational perspective, CCL1-Ig could be a preferred candidate for therapy of autoimmune diseases, because CCR8 + T reg insufficiency (functionally and/or numerically) is likely to be an important contributor to a range of diseases (31) . Conversely, blockade of the CCR8-CCL1 axis may be used as a strategy to enhance anticancer immunity (59).
Methods
Animals. The 6-wk-old female C57BL/6 mice were purchased from Harlan and maintained under specific pathogen-free conditions in our animal facility. FOXp3 GFP mice (internal ribosome entry site-GFP knocked in to the FOXp3 locus, on the C57BL/6 background) were kindly provided by Vijay Kuchroo, Harvard Medical School, Boston, MA. The generation of CCR8 −/− mice has been previously described (by S.A.L.) (29) . The use of animals and experimental protocols were approved by the Animal Care and Use Committee of the Technion.
Antibodies, Cytokines, and Chemokines. Anti-mouse CCL1 neutralizing antibody (AF845), hTGF-β and hIL-2, and all recombinant chemokines (human and mouse) were purchased from R&D Systems.
Human Samples. All human samples were purchased from the Israel Blood Banks. All human biological samples were sourced ethically and their research use was in accordance with the terms of the informed consents.
In Vitro Proliferation Assays. T-cell proliferation was determined either by thymidine incorporation or by carboxyfluorescein succinimidyl ester (CFSE) staining. CFSE labeling studies used a CFSE Cell Division Tracker Kit (423801 BioLegend) according to the manufacturer's protocol and only CD4
+ T eff cells were labeled.
Cell Separation and Suppression Assays. The basic protocol for the mixed lymphocyte suppression assay was conducted according to Collison and Vignali (60) . The detailed protocols for murine and human are specified in SI Methods.
Measurement of Intracellular Calcium Mobilization. A Fluorometric Imaging
Plate Reader (FLIPR, Molecular Devices) was used to detect calcium flux. Data were analyzed using GraphPad Prism (v5) as specified in detail in SI Methods.
Phospho-Specific Flow Cytometry and STAT Inhibitors. Phospho-specific flow cytometry was conducted according to ref. 35 . The biological relevance was verified by using STAT-specific inhibitors. All protocols are specified in detail in SI Methods.
